Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011
Improved overall survival after late recurrence of lung cancer following the introduction of CT-based follow-up for patients treated with curative intent Source: International Congress 2018 – Lung cancer: from early diagnosis to modern monitoring strategies Year: 2018
Rates of treatment response and median survival in advanced non small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
Improved overall survival after early recurrence of lung cancer following the introduction of CT-based follow-up for patients initially treated with curative intent by (chemo)radiotherapy (CRT). Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017
Survival of the operated patients with NSCLC Source: Eur Respir J 2003; 22: Suppl. 45, 367s Year: 2003
Timing of radiotherapy and possible survival benefit in limited disease SCLC patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
The analysis of lung cancer patients (LCP) survival during one-year period after diagnosing of disease Source: Eur Respir J 2006; 28: Suppl. 50, 88s Year: 2006
Long term survivors after radical surgery NSCLC Source: Eur Respir J 2007; 30: Suppl. 51, 468s Year: 2007
Is gender a prognostic factor in long term survival non-small cell lung cancer? Source: Eur Respir J 2002; 20: Suppl. 38, 185s Year: 2002
Importance of CYFRA-21 in estimation of survival of patients with NSCLC Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Impact of radiotherapy on survival rates in chemotherapy treated non small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009
Clinical and biological predictors of progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated by erlotinib in the ERMETIC cohort Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010
Clinical factors of long-term survival in patients with advanced lung cancer Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017
Our operated lung cancer cases and their survival results Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002
Predictors of survival of patients waiting for lung transplantation Source: Eur Respir J 2004; 24: Suppl. 48, 178s Year: 2004
The analysis of lung cancer patients (LCP) survival during 5 year period after diagnosis of disease Source: Eur Respir J 2006; 28: Suppl. 50, 88s Year: 2006
Progression-free survival with first line treatment as prognostic factor of treatment success in subsequent lines in lung adenocarcinoma patients – who´s the „good responder“? Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021
Delays in the diagnosis and treatment of primary lung cancer: are longer delays associated with advanced pathological stage? Source: Annual Congress 2008 - Diagnostic aspects in thoracic oncology Year: 2008
Time trends in treatment and survival of non-small cell lung cancer in The Netherlands Source: Annual Congress 2010 - Quality management for lung cancer patients Year: 2010
Early concurrent chemoradiotherapy for limited small cell lung cancer (LSCLC). Analysis of toxicity and survival of 30 consecutive patients Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002